Evaluation of Mavacamten in Symptomatic Patients Wi Cardiomyopathy

Journal of the American College of Cardiology

75, 2649-2660

DOI: 10.1016/j.jacc.2020.03.064

Citation Report

#	Article	IF	Citations
1	Modelling genetic diseases for drug development: Hypertrophic cardiomyopathy. Pharmacological Research, 2020, 160, 105176.	3.1	12
2	Hypertrophic Cardiomyopathy 2020. Current Cardiology Reports, 2020, 22, 154.	1.3	9
3	2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2020, 76, e159-e240.	1.2	364
4	2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy. Circulation, 2020, 142, e558-e631.	1.6	263
5	Left ventricular dysfunction in heart failure with preserved ejection fractionâ€"molecular mechanisms and impact on right ventricular function. Cardiovascular Diagnosis and Therapy, 2020, 10, 1541-1560.	0.7	14
6	Unraveling the Genotypeâ€Phenotype Relationship in Hypertrophic Cardiomyopathy: Obesityâ€Related Cardiac Defects as a Major Disease Modifier. Journal of the American Heart Association, 2020, 9, e018641.	1.6	16
7	Commentary: In a heart of stone beats a muscle of pure flint. Journal of Thoracic and Cardiovascular Surgery, 2020, , .	0.4	0
8	Effects of mavacamten on Ca²⁺ sensitivity of contraction as sarcomere length varied in human myocardium. British Journal of Pharmacology, 2020, 177, 5609-5621.	2.7	36
9	Characterization and validation of a preventative therapy for hypertrophic cardiomyopathy in a murine model of the disease. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 23113-23124.	3.3	7
10	Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, The, 2020, 396, 759-769.	6.3	481
11	Mavacamten: treatment aspirations in hypertrophic cardiomyopathy. Lancet, The, 2020, 396, 736-737.	6.3	8
12	Mavacamten: a novel small molecule modulator of Î²-cardiac myosin for treatment of hypertrophic cardiomyopathy. Expert Opinion on Investigational Drugs, 2020, 29, 1171-1178.	1.9	13
13	Preventative therapeutic approaches for hypertrophic cardiomyopathy. Journal of Physiology, 2020, 599, 3495-3512.	1.3	6
15	Small Molecules Acting on Myofilaments as Treatments for Heart and Skeletal Muscle Diseases. International Journal of Molecular Sciences, 2020, 21, 9599.	1.8	36
16	Avoiding Burnout From Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2020, 75, 3044-3047.	1.2	5
17	Mavacamten decreases maximal force and Ca²⁺ sensitivity in the N47K-myosin regulatory light chain mouse model of hypertrophic cardiomyopathy. American Journal of Physiology - Heart and Circulatory Physiology, 2021, 320, H881-H890.	1.5	25
18	Editor-in-Chiefâ€™s Top Picks From 2020. Journal of the American College of Cardiology, 2021, 77, 937-997.	1.2	0
19	Emerging Medical Treatment for Hypertrophic Cardiomyopathy. Journal of Clinical Medicine, 2021, 10, 951.	1.0	18

#	Article	IF	Citations
20	Les modulateurs de la myosine cardiaque rÃ©volutionnent la prise en charge de la cardiomyopathie hypertrophique obstructive. Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique, 2021, 2021, 3-5.	0.0	0
21	Novel Myosin-Based Therapies in Hypertrophic Cardiomyopathy. Current Treatment Options in Cardiovascular Medicine, 2021, 23, 1.	0.4	2
22	Cardiopulmonary Exercise Test in Patients with Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 2021, 10, 2312.	1.0	8
23	Contemporary and Future Approaches toÂPrecision Medicine in InheritedÂCardiomyopathies. Journal of the American College of Cardiology, 2021, 77, 2551-2572.	1.2	11
24	Molecular Genetic Basis of Hypertrophic Cardiomyopathy. Circulation Research, 2021, 128, 1533-1553.	2.0	88
25	Quality first in obstructive hypertrophic cardiomyopathy. Lancet, The, 2021, 397, 2440-2441.	6.3	0
26	Mavacamten, a Novel Therapeutic Strategy for Obstructive Hypertrophic Cardiomyopathy. Current Cardiology Reports, 2021, 23, 79.	1.3	17
27	Pathophysiology and Treatment of Hypertrophic Cardiomyopathy: New Perspectives. Current Heart Failure Reports, 2021, 18, 169-179.	1.3	19
28	Prediction of Genotype Positivity in Patients With Hypertrophic Cardiomyopathy Using Machine Learning. Circulation Genomic and Precision Medicine, 2021, 14, e003259.	1.6	8
29	Characteristics of left atrial remodeling in patients with atrial fibrillation and hypertrophic cardiomyopathy in comparison to patients without hypertrophy. Scientific Reports, 2021, 11, 12411.	1.6	4
30	Towards precision medicine in heart failure. Nature Reviews Cardiology, 2021, 18, 745-762.	6.1	34
31	2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy. Journal of Thoracic and Cardiovascular Surgery, 2021, 162, e23-e106.	0.4	33
32	Loss of crossbridge inhibition drives pathological cardiac hypertrophy in patients harboring the TPM1 E192K mutation. Journal of General Physiology, 2021, 153, .	0.9	15
33	Pushing the Limits of Medical Management in HCM: A Review of Current Pharmacological Therapy Options. International Journal of Molecular Sciences, 2021, 22, 7218.	1.8	6
34	Childhood Hypertrophic Cardiomyopathy: A Disease of the Cardiac Sarcomere. Frontiers in Pediatrics, 2021, 9, 708679.	0.9	10
35	Novel therapies in inherited cardiomyopathies. Progress in Pediatric Cardiology, 2021, 63, 101444.	0.2	3
36	Study design and rationale of VALOR-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy who are eligible for septal reduction therapy. American Heart Journal, 2021, 239, 80-89.	1.2	35
37	Randomized controlled trial of perhexiline on regression of left ventricular hypertrophy in patients with symptomatic hypertrophic cardiomyopathy (RESOLVE-HCM trial). American Heart Journal, 2021, 240, 101-113.	1.2	14

#	Article	IF	Citations
39	Hypertrophic Cardiomyopathy: Genetic Testing and Risk Stratification. Current Cardiology Reports, 2021, 23, 9.	1.3	11
41	Hypertrophic Cardiomyopathyã€€â€• A Heterogeneous and Lifelong Disease in the Real World â€•. Circulation Journal, 2020, 84, 1218-1226.	0.7	15
42	Negative inotropic mechanisms of Î²-cardiotoxin in cardiomyocytes by depression of myofilament ATPase activity without activation of the classical Î²-adrenergic pathway. Scientific Reports, 2021, 11, 21154.	1.6	0
43	Hypertrophic Cardiomyopathy: From Phenotype and Pathogenesis to Treatment. Frontiers in Cardiovascular Medicine, 2021, 8, 722340.	1.1	15
44	Two Classes of Myosin Inhibitors, Para-nitroblebbistatin and Mavacamten, Stabilize Î²-Cardiac Myosin in Different Structural and Functional States. Journal of Molecular Biology, 2021, 433, 167295.	2.0	19
45	Lessons From MAVERICK-HCM. Journal of the American College of Cardiology, 2020, 75, 2661-2663.	1.2	2
47	CardiomiopatÃa hipertrÃ³fica en fase de burnout. CES Medicina, 2021, 35, 305-315.	0.1	0
48	Translation of New and Emerging Therapies for Genetic Cardiomyopathies. JACC Basic To Translational Science, 2022, 7, 70-83.	1.9	20
49	Targeted therapies in genetic dilated and hypertrophic cardiomyopathies: from molecular mechanisms to therapeutic targets. A position paper from the Heart Failure Association (HFA) and the Working Group on Myocardial Function of the European Society of Cardiology (ESC). European Journal of Heart Failure, 2022, 24, 406-420.	2.9	22
50	The mechanics of the heart: zooming in on hypertrophic cardiomyopathy and cMyBPâ€C. FEBS Letters, 2022, 596, 703-746.	1.3	12
51	Myosin modulators: emerging approaches for the treatment of cardiomyopathies and heart failure. Journal of Clinical Investigation, 2022, 132, .	3.9	33
52	Left Ventricular Hypertrophy: Etiology-Based Therapeutic Options. Cardiology and Therapy, 2022, 11, 203-230.	1.1	4
53	Targeting the sarcomere in inherited cardiomyopathies. Nature Reviews Cardiology, 2022, 19, 353-363.	6.1	43
54	Mavacamten: A Novel Disease-Specific Treatment for Hypertrophic Cardiomyopathy. Cardiology in Review, 2023, 31, 45-51.	0.6	3
55	Muscle LIM Protein Force-Sensing Mediates Sarcomeric Biomechanical Signaling in Human Familial Hypertrophic Cardiomyopathy. Circulation, 2022, 145, 1238-1253.	1.6	20
56	Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2021, 78, 2518-2532.	1.2	59
57	The Impact of Mavacamten on the Pathophysiology of Hypertrophic Cardiomyopathy: A Narrative Review. American Journal of Cardiovascular Drugs, 2022, 22, 497-510.	1.0	14
58	Future Role of New Negative Inotropic Agents in the Era of Established Surgical Myectomy for Symptomatic Obstructive Hypertrophic Cardiomyopathy. Journal of the American Heart Association, 2022, 11, e024566.	1.6	6

#	Article	IF	Citations
59	Cardiac Myosin Inhibitors as a Novel Treatment Option for Obstructive Hypertrophic Cardiomyopathy: Addressing the Core of the Matter. Journal of the American Heart Association, 2022, 11, e024656.	1.6	18
60	Sarcomere protein modulation: The new frontier in cardiovascular medicine and beyond. European Journal of Internal Medicine, 2022, 102, 1-7.	1.0	5
61	Advances in hypertrophic cardiomyopathy: What the cardiologist needs to know. Revista Portuguesa De Cardiologia, 2022, 41, 499-509.	0.2	4
62	Arrhythmias as Presentation of Genetic Cardiomyopathy. Circulation Research, 2022, 130, 1698-1722.	2.0	19
63	Development of the Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ): A New Patient-Reported Outcome (PRO) Instrument. PharmacoEconomics - Open, 2022, 6, 563-574.	0.9	4
64	Pharmacological Management of Hypertrophic Cardiomyopathy: From Bench to Bedside. Drugs, 2022, 82, 889-912.	4.9	18
66	Exercise training during childhood and adolescence is associated with favorable diastolic function in hypertrophic cardiomyopathy. International Journal of Cardiology, 2022, 364, 65-71.	0.8	8
67	Hypertrophic cardiomyopathy: A modern view on the diagnosis and management of patients (review). Sibirskij Ã¾urnal KliniÃeskoj I Ã¨ksperimentalÊ¹noj Mediciny, 2022, 37, 35-40.	0.1	0
68	Mavacamten: First Approval. Drugs, 2022, 82, 1127-1135.	4.9	32
69	Myosin modulators move forward with FDA approval of mavacamten. , 2022, 1, 595-596.		2
70	Mavacamten, a novel revolutionizing therapy in hypertrophic obstructive cardiomyopathy: A literature review. Revista Portuguesa De Cardiologia, 2022, 41, 693-703.	0.2	3
71	Sex Differences in Cardiomyopathy. Current Cardiovascular Risk Reports, 0, , .	0.8	0
72	Mavacamten, a First-in-Class Cardiac Myosin Inhibitor for Obstructive Hypertrophic Cardiomyopathy. Annals of Pharmacotherapy, 2023, 57, 489-502.	0.9	5
73	Limits to submaximal and maximal exercise in patients with hypertrophic cardiomyopathy. Journal of Applied Physiology, 2022, 133, 787-797.	1.2	3
74	Atrioventricular coupling in hypertrophic cardiomyopathy: Partners in crime for new-onset atrial fibrillation. International Journal of Cardiology, 2022, , .	0.8	0
75	Multinational Federated Learning Approach to Train ECG and Echocardiogram Models for Hypertrophic Cardiomyopathy Detection. Circulation, 2022, 146, 755-769.	1.6	23
77	Efficacy and safety of Mavacamten: A new era in the treatment of hypertrophic cardiomyopathy. European Journal of Internal Medicine, 2022, 106, 144-146.	1.0	1
78	Mavacamten Treatment for Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Current Problems in Cardiology, 2023, 48, 101429.	1.1	6

#	Article	IF	Citations
79	Hypertrophic cardiomyopathy: Mutations to mechanisms to therapies. Frontiers in Physiology, 0, 13, .	1.3	11
80	Hypertrophic cardiomyopathy: an up-to-date snapshot of the clinical drug development pipeline. Expert Opinion on Investigational Drugs, 2022, 31, 1027-1052.	1.9	2
81	Medical treatment of patients with hypertrophic cardiomyopathy: An overview of current and emerging therapy. Archives of Cardiovascular Diseases, 2022, 115, 529-537.	0.7	11
82	Prospects for remodeling the hypertrophic heart with myosin modulators. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	1
83	Contemporary Therapies and Future Directions in the Management of Hypertrophic Cardiomyopathy. Cardiology and Therapy, 2022, 11, 491-507.	1.1	10
84	Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy and the impact of mavacamten. Therapeutic Advances in Chronic Disease, 2022, 13, 204062232211360.	1.1	1
85	Effect of betaâ€blocker therapy on the response to mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy. European Journal of Heart Failure, 2023, 25, 260-270.	2.9	12
86	An evaluation of mavacamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy in adults. Expert Review of Cardiovascular Therapy, 2023, 21, 5-13.	0.6	2
87	Hypertrophic Cardiomyopathy: Current Treatment and Future Options. Current Problems in Cardiology, 2023, 48, 101552.	1.1	4
88	A novel risk model to predict all-cause mortality in patients undergoing percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy. Cardiology Plus, 0, Publish Ahead of Print, .	0.2	0
89	Multi-modality management of hypertrophic cardiomyopathy. Hospital Practice (1995), 2023, 51, 2-11.	0.5	2
90	Myosin Inhibitors. Journal of the American College of Cardiology, 2023, 81, 46-48.	1.2	2
91	Safety and efficacy of mavacamten for treatment of hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomized clinical trials. Egyptian Heart Journal, 2023, 75, .	0.4	4
92	Cardiac myosin inhibitors for hypertrophic cardiomyopathy: shedding light on their clinical potential. Expert Opinion on Investigational Drugs, 2023, 32, 1-4.	1.9	2
93	Effects of Mavacamten on Measures of Cardiopulmonary Exercise Testing Beyond Peak Oxygen Consumption. JAMA Cardiology, 2023, 8, 240.	3.0	15
94	Mechanism based therapies enable personalised treatment of hypertrophic cardiomyopathy. Scientific Reports, 2022, 12, .	1.6	12
95	Genetic causes of heart failure with preserved ejection fraction: emerging pharmacological treatments. European Heart Journal, 2023, 44, 656-667.	1.0	11
96	Temporal trends in the incidence of malignancy in heart failure: a nationwide Danish study. European Heart Journal, 2023, 44, 1124-1132.	1.0	7

#	Article	IF	Citations
97	Familial Hypertrophic Cardiomyopathy: Diagnosis and Management. Vascular Health and Risk Management, 0, Volume 19, 211-221.	1.0	4
98	Review of Mavacamten for Obstructive Hypertrophic Cardiomyopathy and Future Directions. Drug Design, Development and Therapy, 0, Volume 17, 1097-1106.	2.0	2
99	Global research trends of hypertrophic cardiomyopathy from 2000 to 2022: Insights from bibliometric analysis. Frontiers in Cardiovascular Medicine, 0, 10, .	1.1	0
100	Slower Calcium Handling Balances Faster Cross-Bridge Cycling in Human MYBPC3 HCM. Circulation Research, 2023, 132, 628-644.	2.0	6
101	Hypertrophic, Dilated, and Arrhythmogenic Cardiomyopathy: Where Are We?. Biomedicines, 2023, 11, 524.	1.4	6
102	Base editing correction of hypertrophic cardiomyopathy in human cardiomyocytes and humanized mice. Nature Medicine, 2023, 29, 401-411.	15.2	48
103	Cardiac Myosin Inhibitors: Unlocking Potential to Improve Treatment in Hypertrophic Cardiomyopathy. Circulation, 2023, 147, 700-702.	1.6	0
105	Mavacamten â€“ a targeted therapy for hypertrophic cardiomyopathy. Journal of Cardiovascular Pharmacology, 2023, Publish Ahead of Print, .	0.8	2
106	cMyBP-C ablation in human engineered cardiac tissue causes progressive Ca2+-handling abnormalities. Journal of General Physiology, 2023, 155, .	0.9	6
107	Cyclocreatine Phosphate: A Novel Bioenergetic/Anti-Inflammatory Drug That Resuscitates Poorly Functioning Hearts and Protects against Development of Heart Failure. Pharmaceuticals, 2023, 16, 453.	1.7	1
109	Old and new therapeutic solutions in the treatment of hypertrophic cardiomyopathy. European Heart Journal Supplements, 2023, 25, B12-B15.	0.0	3
125	Mechanisms and prognostic impact of myocardial ischaemia in hypertrophic cardiomyopathy. International Journal of Cardiovascular Imaging, 2023, 39, 1979-1996.	0.7	1
126	Apical Hypertrophic Cardiomyopathy: Diagnosis, Natural History, and Management. Cardiology in Review, 0, , .	0.6	1
141	Novel Therapeutic Avenues for Hypertrophic Cardiomyopathy. American Journal of Cardiovascular Drugs, 0, , .	1.0	0
143	Aficamten: A Breakthrough Therapy for Symptomatic Obstructive Hypertrophic Cardiomyopathy. American Journal of Cardiovascular Drugs, 2023, 23, 519-532.	1.0	1
144	Kardiomyopathien. Springer Reference Medizin, 2023, , 1-29.	0.0	0
151	Differentiating Cardiac Troponin Levels During Cardiac Myosin Inhibition or Cardiac Myosin Activation Treatments: Drug Effect or the Canary in the Coal Mine?. Current Heart Failure Reports, 2023, 20, 504-518.	1.3	1
158	Apical hypertrophic cardiomyopathy: pathophysiology, diagnosis and management. Clinical Research in Cardiology, 0, , .	1.5	1

#	Article	IF	Citations
162	Kardiomyopathien. Springer Reference Medizin, 2023, , 365-393.	0.0	0